Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Rocket Pharmaceuticals (RCKT) Leases (2018 - 2025)

Rocket Pharmaceuticals' Leases history spans 8 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Leases fell 92.42% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 92.42%, while the annual FY2025 figure was $3.2 million, 92.42% down from the prior year.
  • Leases for Q4 2025 was $3.2 million at Rocket Pharmaceuticals, down from $40.7 million in the prior quarter.
  • Across five years, Leases topped out at $50.3 million in Q1 2021 and bottomed at $200000.0 in Q1 2023.
  • The 5-year median for Leases is $22.8 million (2024), against an average of $24.2 million.
  • The largest annual shift saw Leases skyrocketed 4379.98% in 2021 before it plummeted 99.58% in 2023.
  • A 5-year view of Leases shows it stood at $1.6 million in 2021, then grew by 25.69% to $2.0 million in 2022, then skyrocketed by 97.82% to $3.9 million in 2023, then skyrocketed by 985.95% to $42.4 million in 2024, then tumbled by 92.42% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Leases are $3.2 million (Q4 2025), $40.7 million (Q3 2025), and $3.8 million (Q2 2025).